Obseva SA OBSV:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 11:33 AM EDT
0.151quote price arrow up+0.0089 (+6.26%)
Volume
488,549
52 week range
0.13 - 3.09
Loading...
  • Open0.145
  • Day High0.17
  • Day Low0.145
  • Prev Close0.1421
  • 52 Week High3.09
  • 52 Week High Date10/04/21
  • 52 Week Low0.13
  • 52 Week Low Date09/23/22

Key Stats

  • Market Cap12.76M
  • Shares Out84.50M
  • 10 Day Average Volume0.96M
  • Dividend-
  • Dividend Yield-
  • Beta0.36
  • YTD % Change-92.43

KEY STATS

  • Open0.145
  • Day High0.17
  • Day Low0.145
  • Prev Close0.1421
  • 52 Week High3.09
  • 52 Week High Date10/04/21
  • 52 Week Low0.13
  • 52 Week Low Date09/23/22
  • Market Cap12.76M
  • Shares Out84.50M
  • 10 Day Average Volume0.96M
  • Dividend-
  • Dividend Yield-
  • Beta0.36
  • YTD % Change-92.43

RATIOS/PROFITABILITY

  • EPS (TTM)-0.78
  • P/E (TTM)-0.19
  • Fwd P/E (NTM)-0.62
  • EBITDA (TTM)-38.598M
  • ROE (TTM)-323.01%
  • Revenue (TTM)24.95M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-255.80%
  • Debt To Equity (MRQ)-1,591.63%

EVENTS

  • Earnings Date11/07/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Obseva SA

 

Profile

MORE
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban...
Frank Verwiel M.D.
Independent Chairman of the Board
Brian O'Callaghan
Chief Executive Officer, Director
Will Brown
Chief Financial Officer
Address
Chemin des Aulx 12
Plan-les-ouates
1228
Switzerland

Top Peers

SYMBOLLASTCHG%CHG
BTX
Brooklyn Immunotherapeutics Inc
0.2326-0.0143-5.7918%
HARP
Harpoon Therapeutics Inc
1.06+0.09+9.27%
SYRS
Syros Pharmaceuticals Inc
5.95-0.49-7.61%
ANGN
Angion Biomedica Corp
0.8826-0.0374-4.0652%
EVFM
Evofem Biosciences Inc
0.172+0.0018+1.06%